The idea that control of bodily functions was regulated almost exclusively by "endocrine" glands and "classical" nerves began to be challenged at the turn of this century, when Bayliss and Starling discovered a "hormonal" principle originating from a supposedly non-endocrine organ, the gastrointestinal tract.' It was then shown that this "hormonal" principle was, indeed, capable of mimicking effects which had been attributed until then to the organ's innervation (Pavlovian concept of nervism). In spite of the revolutionary start in the 1900's and of the early recognition by Feyrter of the existence of a set of specialised "clear" or "endocrine" cells, diffusely distributed throughout the body ("diffuse endocrine system"),2 progress in the recognition of this other facet of neuroendocrinology was hampered by the lack of appropriate tools for its investigation.
The 1960's and 70's were, however, exciting times, as methods were found for the extraction and purification of peptides present in tissues in exceedingly low concentrations, and advanced detection systems were applied. Immunocytochemistry was used for the accurate localisation of active principles in endocrine cells or nerves, or both; radioimmunoassay for the accurate measurement of concentrations of material extractable from tissues; and chromatography for its chemical characterisation.
The concept of the existence of a "diffuse endocrine, or neuroendocrine" or "amine precursor uptake and decarboxylation system" (APUD)3 is now well established and the production of active peptides by the components (endocrine cells or nerves) of this system well recognised.
Morphological methods for the investigation of the diffuse neuroendocrine system SPECIAL HISTOLOGICAL METHODS AND IMMUNOCYTOCHEMISTRY
Numerous special histological methods have been shown to be helpful for showing the presence of endocrine cells and nerves, the preferred methods being those using silver impregnation4-in particular, the Grimelius method, which is capable of showing most peptide producing endocrine cells. Immunocytochemistry, however, has now been established as the method of choice for the study of this novel endocrinology.5
General neuroendocrine markers Several antibodies to specific cytoplasmic components have now been proposed as capable of staining endocrine cells, nerves, or both components of the "diffuse neuroendocrine system" simultaneously.
Neuron specific enolase (NSE)6 is an isozyme of the glycolytic enzyme enolase, originally extracted from the brain. Antibodies to neuron specific enolase immunostain all components of the "diffuse neuroendocrine system". The intensity of immunostaining for neuron specific enolase is unrelated to the presence of secretory granules. The pattern of staining is quite unique as it stains both endocrine cells and their innervation. Because neuron specific enolase is related chemically to an enzyme with glycolytic properties, its presence may be related to the metabolic state of the cell, and because of its cytoplasmic non-granular localisation, immunostaining for neuron specific Some aspects of neuroendocrine pathology enolase is particularly useful for the visualisation of poorly granulated neuroendocrine tissue, such as neuroendocrine tumours of the lung. It is important to be selective when choosing antibodies to neuron specific enolase as this enzyme is a large protein and thus antibodies are likely to react to different epitopes of the entire molecule. It is prohibitive in terms of cost to produce the enzyme synthetically and thus extracted natural material is used for immunisation. It is therefore likely that the antigen will be contaminated with material other than pure NSE and unwanted staining to non-neuroendocrine elements is therefore to be expected. A cocktail of high quality monoclonal antibodies recognising several epitopes of the molecule will be an ideal tool for morphologists. Chromogranins7 A, B, and C are a family of proteins first extracted from the adrenal medulla by Blashko in 1967. It has been shown that chromogranins coexist with catecholamines in the storage granules of adrenal medullary cells and in sympathetic nerves. The nucleotide sequence of human prochromogranin has recently been disclosed8 and shown to contain within it an identical sequence of another recently described secretory protein found in the parathyroid. It has recently been reported that the chromogranins can be released together with catecholamines from normal tissue and from neuroendocrine tumours and that circulating chromogranin immunoreactivity, as measured by radioimmunoassay, may be useful for monitoring sympathoadrenal secretion and for the diagnosis of neuroendocrine tumours.9 Although the functions of the chromogranins have yet to be fully 4 Some aspects of neuroendocrine pathology and extensively visualised by the use of polyclonal and monoclonal antibodies to neurofilaments. '5 -16 Neurofilaments belong to the group of cytoskeletal proteins known as intermediate filaments. These antibodies have been extensively used in immunocytochemistry to visualise the entire innervation as they stain both neuronal cell bodies and nerve fibres. Antibodies to supporting elements, both glial and Schwann cells, are also available-glial fibrillary acidic protein (GFAP) and S-100. GFAP is known to stain astrocytes, in particular those of the central nervous system, whereas S-100 is a good marker for Schwann and glial cells of peripheral tissues. Thus antibodies to neurofilaments, to GFAP, and to S-100 are recommended for visualising the pattern of innervation.
Neurofilaments are of three types with different molecular weights of 68 000, 150 000, and 200 000, the predominant type depending on the degree of maturation of the cell. Monoclonal antibodies are likely to pick up a specific epitope of the polypeptide triplet and therefore may not pick up the entire innervation. Polyclonal antisera of excellent quality are available, and again a good mixture of high quality monoclonal antibodies, recognising the various components of the polypeptide triplet of neurofilaments, may be the ideal route for staining.
Specific peptide markers"7
Antibodies to regulatory peptides are easily available and work well on conventionally fixed and paraffin embedded tissue. They are particularly applicable to the study of endocrine component of the diffuse neuroendocrine system. Furthermore, antibodies are now raised to the various regions of pre-propeptides, thus giving a wider range of localisation possibilities in the study of regulatory peptides. ELECTRON 
MICROSCOPY18
Electron microscopy has been instrumental in showing the existence of dense core secretory granules with specific morphological features, such as size, limiting membrane, electron density and halo. Morphology alone permits a prediction of the type of peptide in a particular secretory granule, but immunocytochemistry, increasingly applied at the electron microscopical level, provides more certainty. Electron immunocytochemical techniques can be broadly divided into pre-embedding and post-embedding methods. The pre-embedding method using peroxidase-antiperoxidase complexes is useful when synaptic contacts or membrane visualisation is required, as the end product of the peroxidase reaction can be made electron dense by osmication of the material following the immunoreaction. For postembedding procedures, a variety of gold labelling 1027 methods are now preferred. Gold particles of various sizes can be attached by covalent forces to immunoglobulins. Different antibodies can be labelled with different gold particles, thus enabling multiple immunostaining procedures to be carried out. The advantage of this technique over the peroxidase method is that the delicate gold particles, when deposited, do not mask the electron-dense neurosecretory granules.
FUNCTIONAL MARKERS
Efforts have recently been centred on the possibility of developing a "functional" morphology and thus expanding the confines of neuroendocrine morphology, which has so far dealt only with the analysis of stored molecules; thus attention has been paid to microscopical imaging tools that could serve to indicate localisation of a specific mRNA species, or peptide binding site, and to visualise intracellular events leading to peptide formation and release. These aims are beginning to be realised by the development of novel techniques, including those of in situ hybridisation, in vitro autoradiography and monitoring of intracellular pH as an indicator of peptide synthesis in progress.
In situ hybridisation19
This novel technique shows specific mRNA molecules directing the synthesis of a given peptide. It is based on the property of complementary sequences of nucleic acids to hybridise within the cell (fig 4a) . Thus a specific probe can be constructed and suitably labelled that will specifically hybridise with defined mRNA molecules. Numerous techniques have been proposed and are broadly divided into radioactive and non-radioactive methods (fig 4b) . The 
Genitourinary system
The genitourinary systems of man and animals has been shown to contain a variety ofregulatory peptides localised in particular in the organ's innervation.23 24 Endocrine cells have also been described, but no particular peptide has been consistently associated with The production of transgenic mice entails the microinjection of a solution of DNA into one of the pronuclei of the fertilised mouse oocyte, after which the injected embryos are reimplanted into the oviducts of pseudopregnant female mice and allowed to develop. About 20% of the newborn mice carry the injected DNA as a heritable genetic element, which they then transmit to their offspring, thus generating a line of transgenic mice which generally manifest the phenotype encoded for by the new gene. Transgenic 1037 mice have proved useful for studying oncogenesis, in particular through the use of oncogenes that are manipulated to be expressed specifically in a certain cell type, thereby eliciting a particular type of tumour.
Human endocrine tumours Pituitary tumours The anterior lobe of the pituitary gland (adenohypophysis) produces at least six hormones, and numerous cell types have been described by special staining, immunocytochemistry, and electron microscopy. 53 The production of novel peptides by the anterior pituitary has recently been recognised.54 These peptides include neurotensin, vasopressin, dynorphin A, and in particular, 7B255 and neuromedin B. Neuromedin B56 is a decapeptide originally isolated from the pig spinal cord and designated "B" because of the similarity of its amino acid sequence to that of bombesin and its ability to stimulate peptide release in a manner similar to that of bombesin. Neuromedin B has been shown to be present in thyrotrophs of the anterior pituitary, and 7B2 has been shown in gonadotrophs and gonadotrophinomas (figs 14a and b). Pancreas The pathology of the endocrine tumours of the pancreas has been extensively described, and readers are referred to several publications.57 -60 The table summarises the main features. Neuroendocrine tumours of the lung have also been extensively reviewed,6' and we will focus only on some interesting recent findings.
Active peptide hormones have been shown to be produced and released from neuroendocrine tumours of the lung; the most commonly found include calcitonin, ACTH, vasopressin, neurotensin, and especially bombesin. Immunoreactivity to bombesin has been shown to be closely associated with small cell carcinoma of the lung. Bombesin may exert a local action on tumour cell surface receptors (autocrine effect).62 The structure of human pro-bombesin has recently been disclosed by molecular biological methods and shown to consist of a signal peptide (bombesin) and a C terminal extended segment. 63 Three mRNAs have been found to code for bombesin, and thus the length of the C terminally extended fragment varies according to the splicing sites of the transcribed message.6465 Specific antibodies to an N-terminal portion (21 amino acids) of the C terminal fragment show stronger immunoreactivity than antibodies to bombesin itself in pulmonary66 and non-pulmonary small cell carcinomas,67 and large concentrations of extractable chemically characterised, C terminal flanking peptide were detected by specific radioimmunoassay. Furthermore, it has recently been shown that immunoreactivity to bombesin has a more or less similar distribution in carcinoids, atypical carcinoids, and small cell carcinomas. By contrast, the C terminal peptide of human pro-bombesin is detectable in a greater proportion of cases of more malignant tumours (small cell carcinomas and atypical carcinoids), raising the question not only as to whether this C terminal fragment is a good pointer to the biological behaviour of the tumour but also whether this may, indeed, be an active part of pro-bombesin molecule with perhaps additional trophic actions. The high expression of the C terminal peptide of probombesin in a large number of small cell carcinomas, which are known generally to be poorly granulated, may indicate an alternative non-granular pathway from peptide synthesis to release (figs 1 5a-c). It would thus be justifiable to speculate that peptides could be produced and voided by a cell, particularly a transformed or otherwise compromised cell, without packaging into storage granules.
Conclusions
We have advanced a great deal from the early descriptions of the diffuse neuroendocrine system to the recognition of the production by components of this system (endocrine cells and nerves) of numerous active peptides sustaining specific sets of functions. The role of this "regulatory peptide system" in experimental and human diseases further advances our understanding of the nature of those diseases and provides evidence that these peptides do, indeed, exert powerful actions that control numerous bodily functions.
